On Friday, Syros Pharmaceuticals Inc (NASDAQ: SYRS) was -12.13% drop from the session before settling in for the closing price of $0.24. A 52-week range for SYRS has been $0.18 – $8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 128.79% over the last five years. When this article was written, the company’s average yearly earnings per share was at 73.32%. With a float of $17.43 million, this company’s outstanding shares have now reached $26.83 million.
The firm has a total of 68 workers. Let’s measure their productivity. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Syros Pharmaceuticals Inc stocks. The insider ownership of Syros Pharmaceuticals Inc is 35.03%, while institutional ownership is 36.36%. The most recent insider transaction that took place on Dec 13 ’24, was worth 4,907. Before that another transaction happened on Dec 13 ’24, when Company’s Affiliate proposed sale 1,000,000 for $0.23, making the entire transaction worth $230,000.
Syros Pharmaceuticals Inc (SYRS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.32% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
You can see what Syros Pharmaceuticals Inc (SYRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Analysing the last 5-days average volume posted by the [Syros Pharmaceuticals Inc, SYRS], we can find that recorded value of 2.14 million was lower than the volume posted last year of 2.37 million. As of the previous 9 days, the stock’s Stochastic %D was 25.11%. Additionally, its Average True Range was 0.12.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 0.36%, which indicates a significant decrease from 7.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.16% in the past 14 days, which was lower than the 375.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3738, while its 200-day Moving Average is $3.8266. Now, the first resistance to watch is $0.2316. This is followed by the second major resistance level at $0.2559. The third major resistance level sits at $0.2720. If the price goes on to break the first support level at $0.1912, it is likely to go to the next support level at $0.1751. Should the price break the second support level, the third support level stands at $0.1508.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
There are 26,832K outstanding shares of the company, which has a market capitalization of 4.89 million. As of now, sales total 9,940 K while income totals -164,570 K. Its latest quarter income was 0 K while its last quarter net income were -6,400 K.
